Payment overview · 2025
General Payments
$3,351.14
46 reported records · 29 companies
Healthcare provider profile · identity verified
Sameer P Desai, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Hematology & Oncology · SOMERSET, NJ · NPI 1487776373
Verified facts
What the public records show
CMS Open Payments records show Sameer P Desai, MD received $3,351.14 in general payments during 2025 across 46 reported records.
AstraZeneca Pharmaceuticals LP accounted for 42.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 33 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Brukinsa, Jakafi, Nerlynx, Venclexta, Xtandi.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported IMBRUVICA as an associated drug or biological on 15599 records involving 6881 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Imbruvica by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LUPRON DEPOT as an associated drug or biological on 6475 records involving 3205 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Lupron Depot by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VENCLEXTA as an associated drug or biological on 10417 records involving 4944 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Venclexta by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Xtandi as an associated drug or biological on 11345 records involving 5418 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Xtandi by this doctor in 2024.
BeOne Medicines USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRUKINSA as an associated drug or biological on 10251 records involving 4941 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Brukinsa by this doctor in 2024.
Celgene Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 25 records involving 24 distinct recipient NPIs. Public Medicare Part D data also shows 114 claims for Eliquis by this doctor in 2024.
Celgene Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported POMALYST as an associated drug or biological on 282 records involving 237 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Pomalyst by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 114 claims for Eliquis by this doctor in 2024.
Incyte Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JAKAFI as an associated drug or biological on 14854 records involving 6477 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Jakafi by this doctor in 2024.
Janssen Biotech, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported IMBRUVICA as an associated drug or biological on 47 records involving 33 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Imbruvica by this doctor in 2024.
Janssen Biotech, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 24 records involving 23 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Xarelto by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 114 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XTANDI as an associated drug or biological on 19368 records involving 7657 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Xtandi by this doctor in 2024.
PUMA BIOTECHNOLOGY, INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NERLYNX as an associated drug or biological on 5139 records involving 3271 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Nerlynx by this doctor in 2024.
Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GAMMAGARD LIQUID as an associated drug or biological on 29 records involving 8 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Gammagard Liquid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $1,435.05 | 42.8% | 4 | 2025 |
| TAIHO ONCOLOGY, INC. | Unresolved — no canonical attribution shown | $1,130.00 | 33.7% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $66.26 | 2.0% | 4 | 2025 |
| Aveo Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $60.41 | 1.8% | 2 | 2025 |
| Ipsen Biopharmaceuticals, Inc | Unresolved — no canonical attribution shown | $56.21 | 1.7% | 3 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $46.94 | 1.4% | 2 | 2025 |
| JAZZ PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $37.75 | 1.1% | 2 | 2025 |
| Telix Pharmaceuticals | Unresolved — no canonical attribution shown | $36.95 | 1.1% | 2 | 2025 |
| Regeneron Healthcare Solutions, Inc. | Unresolved — no canonical attribution shown | $36.19 | 1.1% | 2 | 2025 |
| Blueprint Medicines Corporation | Unresolved — no canonical attribution shown | $35.94 | 1.1% | 2 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $34.56 | 1.0% | 2 | 2025 |
| PharmaEssentia USA Corporation | Unresolved — no canonical attribution shown | $33.90 | 1.0% | 2 | 2025 |
| Celgene Corporation | Unresolved — no canonical attribution shown | $33.66 | 1.0% | 2 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $32.06 | 1.0% | 1 | 2025 |
| Novocure Inc. | Unresolved — no canonical attribution shown | $26.01 | 0.8% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $22.69 | 0.7% | 1 | 2025 |
| Pharmacosmos Therapeutics Inc. | Unresolved — no canonical attribution shown | $21.99 | 0.7% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $21.68 | 0.7% | 1 | 2025 |
| Incyte Corporation | Unresolved — no canonical attribution shown | $19.50 | 0.6% | 1 | 2025 |
| PUMA BIOTECHNOLOGY, INC. | Unresolved — no canonical attribution shown | $18.68 | 0.6% | 1 | 2025 |
| Exelixis Inc. | Unresolved — no canonical attribution shown | $18.03 | 0.5% | 1 | 2025 |
| Azurity Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $17.22 | 0.5% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $17.10 | 0.5% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $16.94 | 0.5% | 1 | 2025 |
| Deciphera Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $15.95 | 0.5% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $15.77 | 0.5% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $15.26 | 0.5% | 1 | 2025 |
| BeOne Medicines USA, Inc. | Unresolved — no canonical attribution shown | $14.82 | 0.4% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $13.62 | 0.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Consulting Fee | $2,505.00 | 2 |
| Food and Beverage | $846.14 | 44 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TAGRISSO Normalized: tagrisso |
Drug | AstraZeneca Pharmaceuticals LP | $1,375.00 | 1 | 2025 |
Source payment records
|
|||||
| LONSURF Normalized: lonsurf |
Drug | TAIHO ONCOLOGY, INC. | $1,130.00 | 1 | 2025 |
Source payment records
|
|||||
| PADCEV Normalized: padcev |
Biological, Drug | Astellas Pharma US Inc, PFIZER INC. | $64.40 | 4 | 2025 |
Source payment records
|
|||||
| FOTIVDA Normalized: fotivda |
Drug | Aveo Pharmaceuticals, Inc. | $60.41 | 2 | 2025 |
Source payment records
|
|||||
| Onivyde Normalized: onivyde |
Drug | Ipsen Biopharmaceuticals, Inc | $56.21 | 3 | 2025 |
Source payment records
|
|||||
| CERDELGA Normalized: cerdelga |
Drug | GENZYME CORPORATION | $46.94 | 2 | 2025 |
Source payment records
|
|||||
| CEREZYME Normalized: cerezyme |
Biological | GENZYME CORPORATION | $46.94 | 2 | 2025 |
Source payment records
|
|||||
| ZEPZELCA Normalized: zepzelca |
Drug | JAZZ PHARMACEUTICALS INC. | $37.75 | 2 | 2025 |
Source payment records
|
|||||
| ILLUCCIX Normalized: illuccix |
Drug | Telix Pharmaceuticals | $36.95 | 2 | 2025 |
Source payment records
|
|||||
| LIBTAYO Normalized: libtayo |
Biological | Regeneron Healthcare Solutions, Inc. | $36.19 | 2 | 2025 |
Source payment records
|
|||||
| AYVAKIT Normalized: ayvakit |
Drug | Blueprint Medicines Corporation | $35.94 | 2 | 2025 |
Source payment records
|
|||||
| Lenvima Normalized: lenvima |
Drug | Eisai Inc. | $34.56 | 2 | 2025 |
Source payment records
|
|||||
| BESREMI Normalized: besremi |
Drug | PharmaEssentia USA Corporation | $33.90 | 2 | 2025 |
Source payment records
|
|||||
| REBLOZYL Normalized: reblozyl |
Biological | Celgene Corporation | $33.66 | 2 | 2025 |
Source payment records
|
|||||
| TALVEY Normalized: talvey |
Biological | Janssen Biotech, Inc. | $32.06 | 1 | 2025 |
Source payment records
|
|||||
| Optune Lua (NovoTTF-200T) Normalized: optune lua novottf 200t |
Device | Novocure Inc. | $26.01 | 1 | 2025 |
Source payment records
|
|||||
| ALUNBRIG Normalized: alunbrig |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $22.69 | 1 | 2025 |
Source payment records
|
|||||
| MONOFERRIC Normalized: monoferric |
Drug | Pharmacosmos Therapeutics Inc. | $21.99 | 1 | 2025 |
Source payment records
|
|||||
| Nubeqa Normalized: nubeqa |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $21.68 | 1 | 2025 |
Source payment records
|
|||||
| Xofigo Normalized: xofigo |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $21.68 | 1 | 2025 |
Source payment records
|
|||||
| JAKAFI Normalized: jakafi |
Drug | Incyte Corporation | $19.50 | 1 | 2025 |
Source payment records
|
|||||
| NERLYNX Normalized: nerlynx |
Drug | PUMA BIOTECHNOLOGY, INC. | $18.68 | 1 | 2025 |
Source payment records
|
|||||
| CABOMETYX Normalized: cabometyx |
Drug | Exelixis Inc. | $18.03 | 1 | 2025 |
Source payment records
|
|||||
| Xtandi Normalized: xtandi |
Drug | Astellas Pharma US Inc | $17.63 | 1 | 2025 |
Source payment records
|
|||||
| DANZITEN Normalized: danziten |
Drug | Azurity Pharmaceuticals, Inc. | $17.22 | 1 | 2025 |
Source payment records
|
|||||
| VIVIMUSTA Normalized: vivimusta |
Drug | Azurity Pharmaceuticals, Inc. | $17.22 | 1 | 2025 |
Source payment records
|
|||||
| SCEMBLIX Normalized: scemblix |
Drug | Novartis Pharmaceuticals Corporation | $16.94 | 1 | 2025 |
Source payment records
|
|||||
| CALQUENCE Normalized: calquence |
Drug | AstraZeneca Pharmaceuticals LP | $15.99 | 1 | 2025 |
Source payment records
|
|||||
| QINLOCK Normalized: qinlock |
Drug | Deciphera Pharmaceuticals Inc. | $15.95 | 1 | 2025 |
Source payment records
|
|||||
| TGCT Normalized: tgct |
Drug | Deciphera Pharmaceuticals Inc. | $15.95 | 1 | 2025 |
Source payment records
|
|||||
| OJJAARA Normalized: ojjaara |
Drug | GlaxoSmithKline, LLC. | $15.26 | 1 | 2025 |
Source payment records
|
|||||
| BRUKINSA Normalized: brukinsa |
Drug | BeOne Medicines USA, Inc. | $14.82 | 1 | 2025 |
Source payment records
|
|||||
| VENCLEXTA Normalized: venclexta |
Drug | ABBVIE INC. | $13.62 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| BRUKINSA brukinsa |
2025 | Brukinsa | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JAKAFI jakafi |
2025 | Jakafi | 2024 | 25 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| NERLYNX nerlynx |
2025 | Nerlynx | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VENCLEXTA venclexta |
2025 | Venclexta | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Xtandi xtandi |
2025 | Xtandi | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | IMBRUVICA open payments reported associated product |
CMS Open Payments — General Payments 15599 supporting records · 6881 recipient NPIs · example record 1201352838 |
Imbruvica · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LUPRON DEPOT open payments reported associated product |
CMS Open Payments — General Payments 6475 supporting records · 3205 recipient NPIs · example record 1201352804 |
Lupron Depot · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VENCLEXTA open payments reported associated product |
CMS Open Payments — General Payments 10417 supporting records · 4944 recipient NPIs · example record 1201353144 |
Venclexta · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Xtandi open payments reported associated product |
CMS Open Payments — General Payments 11345 supporting records · 5418 recipient NPIs · example record 1238560686 |
Xtandi · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| BeOne Medicines USA, Inc. Exact reporting entity; no affiliate inference |
2025 | BRUKINSA open payments reported associated product |
CMS Open Payments — General Payments 10251 supporting records · 4941 recipient NPIs · example record 1202883638 |
Brukinsa · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Celgene Corporation Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 25 supporting records · 24 recipient NPIs · example record 1184385048 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
114 | 22 |
| Celgene Corporation Exact reporting entity; no affiliate inference |
2025 | POMALYST open payments reported associated product |
CMS Open Payments — General Payments 282 supporting records · 237 recipient NPIs · example record 1184378437 |
Pomalyst · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
114 | 22 |
| Incyte Corporation Exact reporting entity; no affiliate inference |
2025 | JAKAFI open payments reported associated product |
CMS Open Payments — General Payments 14854 supporting records · 6477 recipient NPIs · example record 1225959940 |
Jakafi · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Janssen Biotech, Inc. Exact reporting entity; no affiliate inference |
2025 | IMBRUVICA open payments reported associated product |
CMS Open Payments — General Payments 47 supporting records · 33 recipient NPIs · example record 1174328453 |
Imbruvica · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Janssen Biotech, Inc. Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 24 supporting records · 23 recipient NPIs · example record 1174259978 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
56 | 11 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
114 | 22 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | XTANDI open payments reported associated product |
CMS Open Payments — General Payments 19368 supporting records · 7657 recipient NPIs · example record 1228794230 |
Xtandi · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| PUMA BIOTECHNOLOGY, INC. Exact reporting entity; no affiliate inference |
2025 | NERLYNX open payments reported associated product |
CMS Open Payments — General Payments 5139 supporting records · 3271 recipient NPIs · example record 1251741512 |
Nerlynx · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference |
2025 | GAMMAGARD LIQUID open payments reported associated product |
CMS Open Payments — General Payments 29 supporting records · 8 recipient NPIs · example record 1223786557 |
Gammagard Liquid · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Anastrozole | Anastrozole | 138 | 46 |
| Eliquis | Apixaban | 114 | 22 |
| Aranesp | Darbepoetin Alfa In Polysorbat | 91 | 20 |
| Hydroxyurea | Hydroxyurea | 91 | 19 |
| Procrit | Epoetin Alfa | 78 | 17 |
| Neulasta | Pegfilgrastim | 61 | 16 |
| Xarelto | Rivaroxaban | 56 | 11 |
| Prednisone | Prednisone | 53 | 19 |
| Abiraterone Acetate | Abiraterone Acetate | 44 | suppressed |
| Revlimid | Lenalidomide | 38 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 35 | suppressed |
| Anagrelide Hcl | Anagrelide Hcl | 34 | suppressed |
| Folic Acid | Folic Acid | 25 | 11 |
| Jakafi | Ruxolitinib Phosphate | 25 | suppressed |
| Gabapentin | Gabapentin | 23 | suppressed |
| Lupron Depot | Leuprolide Acetate | 23 | suppressed |
| Truxima | Rituximab-Abbs | 23 | suppressed |
| Potassium Chloride | Potassium Chloride | 22 | suppressed |
| Amlodipine Besylate | Amlodipine Besylate | 21 | suppressed |
| Akynzeo | Fosnetupitant/Palonosetron | 19 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 18 | suppressed |
| Alprazolam | Alprazolam | 17 | suppressed |
| Dexamethasone | Dexamethasone | 16 | suppressed |
| Letrozole | Letrozole | 16 | suppressed |
| Brukinsa | Zanubrutinib | 15 | suppressed |
| Gammagard Liquid | Immun Glob G(Igg)/Gly/Iga Ov50 | 15 | suppressed |
| Ondansetron Odt | Ondansetron | 15 | suppressed |
| Levothyroxine Sodium | Levothyroxine Sodium | 14 | suppressed |
| Xtandi | Enzalutamide | 14 | suppressed |
| Acyclovir | Acyclovir | 13 | suppressed |
| Diphenhydramine Hcl | Diphenhydramine Hcl | 13 | suppressed |
| Octagam | Immun Globg(Igg)/Malt/Iga Ov50 | 13 | suppressed |
| Pomalyst | Pomalidomide | 13 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 13 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 13 | suppressed |
| Venclexta | Venetoclax | 13 | suppressed |
| Imbruvica | Ibrutinib | 12 | suppressed |
| Lenalidomide | Lenalidomide | 12 | suppressed |
| Riabni | Rituximab-Arrx | 12 | suppressed |
| Sandostatin Lar Depot | Octreotide Acetate,mi-Spheres | 12 | suppressed |
| Tamoxifen Citrate | Tamoxifen Citrate | 12 | suppressed |
| Zarxio | Filgrastim-Sndz | 12 | suppressed |
| Nerlynx | Neratinib Maleate | 11 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 11 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $3,351.14 · 46 records | AstraZeneca Pharmaceuticals LP | ALUNBRIG, AYVAKIT, BESREMI, BRUKINSA, CABOMETYX, CALQUENCE, CERDELGA, CEREZYME, DANZITEN, FOTIVDA, ILLUCCIX, JAKAFI, LIBTAYO, LONSURF, Lenvima, MONOFERRIC, NERLYNX, Nubeqa, OJJAARA, Onivyde, Optune Lua (NovoTTF-200T), PADCEV, QINLOCK, REBLOZYL, SCEMBLIX, TAGRISSO, TALVEY, TGCT, VENCLEXTA, VIVIMUSTA, Xofigo, Xtandi, ZEPZELCA | 15 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Brukinsa play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error